Expert Opinion on Drug Discovery

SJR Rank #3,202H-index: 99SJR: 1.287Best quartile: Q1
Journal website: aims, scope and author guidelines
Publisher

Taylor and Francis Ltd.

Country

United Kingdom

Type

journal

SJR by Edition

2022202500.350.71.051.4

Subject Categories

  • Drug DiscoveryQ1

Areas: Pharmacology, Toxicology and Pharmaceutics

Most published research topics

Computational Drug Discovery MethodsReceptor Mechanisms and SignalingCell Image Analysis TechniquesMonoclonal and Polyclonal Antibodies ResearchClick Chemistry and ApplicationsChemical Synthesis and AnalysisProtein Degradation and InhibitorsProtein Structure and DynamicsBioinformatics and Genomic NetworksPharmacogenetics and Drug Metabolism

Source: OpenAlex

Publication Statistics

2025 Docs3-Year DocsCitable Docs085170255340

Documents per Year

202220250306090120

Detailed Information

ISSN

1746-045X, 1746-0441

SJR Best Quartile

Q1

Region

Western Europe

Citations per Document (2 years)

6.52

References per Document

109.72

Coverage

2006-2026

Scope

Expert Opinion on Drug Discovery (ISSN 1746-0441 [print], 1746-045X [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on novel technologies involved in the drug discovery process, leading to new leads and reduced attrition rates. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering chemoinformatics; bioinformatics; assay development; novel screening technologies; in vitro/in vivo models; structure-based drug design; systems biology Drug Case Histories examining the steps involved in the preclinical and clinical development of a particular drug The audience consists of scientists and managers in the healthcare and pharmaceutical industry, academic pharmaceutical scientists and other closely related professionals looking to enhance the success of their drug candidates through optimisation at the preclinical level.

Metrics from SCImago Journal Rank 2025. View on SCImago